Market Cap 491.64M
Revenue (ttm) 403.14M
Net Income (ttm) -22.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 41.74
Profit Margin -5.63%
Debt to Equity Ratio -0.50
Volume 7,049,500
Avg Vol 5,931,170
Day's Range N/A - N/A
Shares Out 257.41M
Stochastic %K 22%
Beta 1.17
Analysts Sell
Price Target $6.97

Company Profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
profitsforall
profitsforall Apr. 25 at 12:20 PM
$ESPR It WAS discussed...several weeks ago. The general conclusion was that the tariffs would have NO IMPACT on ESPR.
0 · Reply
ShortESPR
ShortESPR Apr. 25 at 12:16 PM
$ESPR How do we feel about this: Sheldon and Ben have bought ZERO stock. However every year now they are taking the employees to exotic places and the longs are paying for it. They were just in Las Vegas and last year Disney World. How do guys feel about this misuse of funds? NASCAR sponsorship cost millions as well. Dont hate Sheldon and Ben, they are having so much fun I am told.
1 · Reply
ShortESPR
ShortESPR Apr. 25 at 12:14 PM
$ESPR It is crazy at 1.94 that the Market Cap is a staggering half a billion dollars. The more they dilute, the smaller your slice is. Next Dilution should be about 300 million shares will be added. Who is ready to buy more ?
0 · Reply
ShortESPR
ShortESPR Apr. 25 at 11:26 AM
$ESPR Is this goal for the stock to actually go up? Axing for a friend. This stock just seems to love to go down. Is there a way to make money betting against the stock going up? Axing for another friend
0 · Reply
Stock765
Stock765 Apr. 25 at 11:16 AM
$ESPR Is the statin monopoly slowly fading? This kind of volatility in the share price is quite exciting and certainly won't stop me from participating here. I believe positive headlines are coming soon and short sellers will have to cover. Know what you own.
0 · Reply
Xuan0821
Xuan0821 Apr. 25 at 7:53 AM
$ESPR I want to ask why no one discussed the impact of Trump's drug tariff? How many tariffs will ESPR's overseas OEM drugs face? 20% or 100%?
0 · Reply
Petey3163
Petey3163 Apr. 25 at 2:57 AM
$ESPR why did management push Q1 profitability so hard and then give a random Sunday in February to squash all that hope? Now we haven’t heard anymore about profitability and the stock Has since tanked. Surely Sheldon snd the board look at the stock price daily. Do they not care or have any moral sense to the shareholders that pay their bills? Even if the new acquisition was shitty why didn’t Sheldon give an outlook on the company as to what they wanted to accomplish with it. Why do we never get any insight on what the company. Is this typical for how a bio tech operates?
1 · Reply
omar_progressivetrading
omar_progressivetrading Apr. 25 at 2:22 AM
$ESPR — What a ride this has been… and we’re just getting started. Sitting fully loaded with a low average while the noise comes from every direction, low-key bears and aggressive ones alike, all throwing their best shots without realizing this was never about pennies. That mindset alone separates the players from the spectators. Even more telling… some “so-called longs” folded pieces of their position only to circle back, chasing crumbs. The irony writes itself. Meanwhile, I study the field. Watching my twin following over 1K ESPR accounts gives me clarity, most follow sentiment, very few lead with conviction. That’s the real gap. We, the Moon Kids, are built differently. Positioned. Patient. Unshaken. Not here for small flips… here for the long game, because we understand what’s unfolding beneath the surface. So I’ll ask again! Where the real Long-Term Moon Kids at? Beach WE ARE BUILT DIFFERENT! To The Moon & Beyond! 🫡 🌖
0 · Reply
Traildog19
Traildog19 Apr. 25 at 1:26 AM
$ESPR retest 1.81 next week.
1 · Reply
meistermell
meistermell Apr. 25 at 1:20 AM
$ESPR the corstasis purchase was anything but stupid and isn't the reason for the volatility. They will be profitable Q3, Q4 at the latest and Enbumyst will eventually bring in double of what they paid for it yearly at the minimum, for many years to come. Their balance sheet is fine, it's just management not PRing their progress, continued strategy and conviction often enough, reserving PRs jolting the pps for after option grants for employees and bod. Many companies would have issued a PR addressing such volatility, and the fact that shorts are just starting to cover seems to indicate they know about the timing. We're close though as scripts growth can't be hidden any longer, we are seeing 15%+ in Q2 and will likely see 20%-30% in Q3. And all this is amplified by reduced cogs due to the tech transfer. Do the math
0 · Reply
Latest News on ESPR
Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 9:29 PM EDT - 7 months ago

Esperion Announces Pricing of Public Offering of Common Stock


Esperion Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 7 months ago

Esperion Announces Proposed Public Offering of Common Stock


Top 2 Health Care Stocks That May Plunge This Month

Sep 5, 2025, 10:39 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB


Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 10 months ago

Esperion Appoints Craig Thompson to Board of Directors


Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing


Esperion to Participate in Upcoming June Investor Conferences

May 23, 2024, 9:00 AM EDT - 2 years ago

Esperion to Participate in Upcoming June Investor Conferences


Esperion Reports First Quarter 2024 Financial Results

May 7, 2024, 6:00 AM EDT - 2 years ago

Esperion Reports First Quarter 2024 Financial Results


profitsforall
profitsforall Apr. 25 at 12:20 PM
$ESPR It WAS discussed...several weeks ago. The general conclusion was that the tariffs would have NO IMPACT on ESPR.
0 · Reply
ShortESPR
ShortESPR Apr. 25 at 12:16 PM
$ESPR How do we feel about this: Sheldon and Ben have bought ZERO stock. However every year now they are taking the employees to exotic places and the longs are paying for it. They were just in Las Vegas and last year Disney World. How do guys feel about this misuse of funds? NASCAR sponsorship cost millions as well. Dont hate Sheldon and Ben, they are having so much fun I am told.
1 · Reply
ShortESPR
ShortESPR Apr. 25 at 12:14 PM
$ESPR It is crazy at 1.94 that the Market Cap is a staggering half a billion dollars. The more they dilute, the smaller your slice is. Next Dilution should be about 300 million shares will be added. Who is ready to buy more ?
0 · Reply
ShortESPR
ShortESPR Apr. 25 at 11:26 AM
$ESPR Is this goal for the stock to actually go up? Axing for a friend. This stock just seems to love to go down. Is there a way to make money betting against the stock going up? Axing for another friend
0 · Reply
Stock765
Stock765 Apr. 25 at 11:16 AM
$ESPR Is the statin monopoly slowly fading? This kind of volatility in the share price is quite exciting and certainly won't stop me from participating here. I believe positive headlines are coming soon and short sellers will have to cover. Know what you own.
0 · Reply
Xuan0821
Xuan0821 Apr. 25 at 7:53 AM
$ESPR I want to ask why no one discussed the impact of Trump's drug tariff? How many tariffs will ESPR's overseas OEM drugs face? 20% or 100%?
0 · Reply
Petey3163
Petey3163 Apr. 25 at 2:57 AM
$ESPR why did management push Q1 profitability so hard and then give a random Sunday in February to squash all that hope? Now we haven’t heard anymore about profitability and the stock Has since tanked. Surely Sheldon snd the board look at the stock price daily. Do they not care or have any moral sense to the shareholders that pay their bills? Even if the new acquisition was shitty why didn’t Sheldon give an outlook on the company as to what they wanted to accomplish with it. Why do we never get any insight on what the company. Is this typical for how a bio tech operates?
1 · Reply
omar_progressivetrading
omar_progressivetrading Apr. 25 at 2:22 AM
$ESPR — What a ride this has been… and we’re just getting started. Sitting fully loaded with a low average while the noise comes from every direction, low-key bears and aggressive ones alike, all throwing their best shots without realizing this was never about pennies. That mindset alone separates the players from the spectators. Even more telling… some “so-called longs” folded pieces of their position only to circle back, chasing crumbs. The irony writes itself. Meanwhile, I study the field. Watching my twin following over 1K ESPR accounts gives me clarity, most follow sentiment, very few lead with conviction. That’s the real gap. We, the Moon Kids, are built differently. Positioned. Patient. Unshaken. Not here for small flips… here for the long game, because we understand what’s unfolding beneath the surface. So I’ll ask again! Where the real Long-Term Moon Kids at? Beach WE ARE BUILT DIFFERENT! To The Moon & Beyond! 🫡 🌖
0 · Reply
Traildog19
Traildog19 Apr. 25 at 1:26 AM
$ESPR retest 1.81 next week.
1 · Reply
meistermell
meistermell Apr. 25 at 1:20 AM
$ESPR the corstasis purchase was anything but stupid and isn't the reason for the volatility. They will be profitable Q3, Q4 at the latest and Enbumyst will eventually bring in double of what they paid for it yearly at the minimum, for many years to come. Their balance sheet is fine, it's just management not PRing their progress, continued strategy and conviction often enough, reserving PRs jolting the pps for after option grants for employees and bod. Many companies would have issued a PR addressing such volatility, and the fact that shorts are just starting to cover seems to indicate they know about the timing. We're close though as scripts growth can't be hidden any longer, we are seeing 15%+ in Q2 and will likely see 20%-30% in Q3. And all this is amplified by reduced cogs due to the tech transfer. Do the math
0 · Reply
omar_progressivetrading
omar_progressivetrading Apr. 25 at 12:35 AM
$ESPR — There was a time when one of the sharpest “Data Moon Kids” in the game consistently shared incredibly detailed PDFs, tracking everything with precision and discipline. While he’s no longer posting, I came across one of his pieces that still offers powerful insight into what may lie ahead from a data standpoint. For clarity, nothing has been altered or updated, it remains exactly as originally shared. But even today, it stands out as one of the most valuable, well-structured resources I’ve seen. The level of detail and consistency in tracking is simply next level. Every time I line it up against the charts, the broader trajectory still points toward long-term alignment. No matter which side you’re on, it’s worth reviewing with an open mind. At the end of the day, that’s what defines us Moon Kids, we’re not here for noise, we’re here for the long game. To The Moon & Beyond! 🫡 🌖
0 · Reply
OldManLogan
OldManLogan Apr. 25 at 12:26 AM
$ESPR The decline in shorts while price contined to drop likely means share were covered via warrants exercise... that said, there's a lot of shorts left over even after accounting for any remaining warrants... and it will take waaaay more than 7 days to cover because most of the volume we see is just hot potato back and forth. If Sheldon was a master strategist you could really incinerate the shorts with just the right timing of newsflow... dare to dream, lol.
3 · Reply
RunHorse
RunHorse Apr. 25 at 12:03 AM
$ESPR While shareholders suffer Sheldon & Co. are finishing up an all expense paid trip to Las Vegas. Beats last year’s all expense paid trip to Disney World.
2 · Reply
Petey3163
Petey3163 Apr. 24 at 11:13 PM
$ESPR they don’t seem to be in much of a hurry unfortunately
1 · Reply
BBRC
BBRC Apr. 24 at 10:54 PM
$ESPR Another beautiful buying opportunity today. It looks like many took advantage.
0 · Reply
meistermell
meistermell Apr. 24 at 10:37 PM
$ESPR not a chartist, but leaned out before saying 1.80s/1.90s will hold, sticking to it, today was more confirmation. We should be one overall big green market day or PR away from vaulting over 2 again. Today was not it, biotech indices were down around 1% the whole day, so good rebound on decent volume today
0 · Reply
Mupersak1234
Mupersak1234 Apr. 24 at 10:22 PM
$ESPR Serious question for the chartists…are there any major support levels? Are we looking at closing a gap down from here?
1 · Reply
Blocktatch
Blocktatch Apr. 24 at 9:26 PM
$ESPR Is there any call on Monday?
0 · Reply
Petey3163
Petey3163 Apr. 24 at 9:12 PM
$ESPR there’s no way they bought another company for 75mm to worsen the company. They know what the outlook of the company is
1 · Reply
Bear0927
Bear0927 Apr. 24 at 9:00 PM
$ESPR The triple combination approval process really only has to show bioequivalence. ESPR can utilize DSE's studies to this end I believe. The pathway to approval is much, much shorter.
0 · Reply
MichelleBe
MichelleBe Apr. 24 at 8:42 PM
$ESPR so much dilution that the market cap is already at half a billion at $1.90. Smfh. If management had just sold their damn drugs and proved that they can be profitable, the stock would be trading higher. Instead, they acquired another drug for $75MM and worsened their balance sheet. How damn stupid are these morons.
1 · Reply
Hawaiianinvesta
Hawaiianinvesta Apr. 24 at 8:36 PM
$ESPR god dam these mofos are trying hard to push us off our shares.
0 · Reply